Andrew J K Ostor
Overview
Explore the profile of Andrew J K Ostor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
1143
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Navarro-Compan V, Van den Bosch F, Sampaio-Barros P, Ostor A, Parikh B, Kato K, et al.
RMD Open
. 2025 Mar;
11(1).
PMID: 40037923
Objectives: Early disease activity control with targeted therapies may improve long-term outcomes in axial spondyloarthritis (axSpA). Here, we evaluated the efficacy of upadacitinib in patients with axSpA with shorter versus...
2.
Bhurani M, Hall S, Gibson A, Ostor A
Intern Med J
. 2024 May;
54(5):838-839.
PMID: 38757207
No abstract available.
3.
Lewis J, Ostor A
Rheumatology (Oxford)
. 2023 Oct;
62(SI3):SI237-SI241.
PMID: 37871915
Polypharmacy is increasingly common in rheumatology due to the complex nature of managing chronic autoimmune diseases. To date there has been limited research into the impact of polypharmacy on rheumatology...
4.
Ostor A, Soliman A, Papp K, Padilla B, Wang Z, Eldred A, et al.
RMD Open
. 2022 Jun;
8(2).
PMID: 35701011
Objectives: Determine the impact of 24-week risankizumab (RZB) versus placebo (PBO) on patient-reported outcomes (PROs) in patients with psoriatic arthritis (PsA) and inadequate response to one or two biologics (Bio-IR)...
5.
McInnes I, Ostor A, Mease P, Tillett W, Baraliakos X, De Vlam K, et al.
RMD Open
. 2022 Mar;
8(1).
PMID: 35332058
Objective: Evaluate the effect of upadacitinib on pain outcomes in patients with active psoriatic arthritis (PsA) or ankylosing spondylitis (AS) across 3 randomised trials (SELECT-PsA 1 and 2 for PsA;...
6.
Findeisen K, Sewell J, Ostor A
Biologics
. 2021 Aug;
15:343-352.
PMID: 34413630
Rheumatoid arthritis (RA) is a disease characterised by inflammation of synovial joints and poses a substantial healthcare burden on both the individual and society. One of the most significant shifts...
7.
Bykerk V, Ostor A, Alvaro-Gracia J, Pavelka K, Ivorra J, Nurmohamed M, et al.
Clin Rheumatol
. 2019 Apr;
38(9):2411-2421.
PMID: 31028551
Objective: To assess the long-term safety, tolerability, and effectiveness of tocilizumab (TCZ) as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in clinical practice in patients with...
8.
Rischin A, Brady B, McLean C, Ostor A
Intern Med J
. 2018 Dec;
48(12):1550-1552.
PMID: 30517989
No abstract available.
9.
Edwards C, Ostor A, Naisbett-Groet B, Kiely P
Rheumatology (Oxford)
. 2017 Nov;
57(1):84-91.
PMID: 29155973
Objective: To explore whether tocilizumab + tapering MTX has comparable efficacy and safety vs tocilizumab + stable MTX in adult RA patients with inadequate response to MTX. Methods: This randomized,...
10.
Van den Bosch F, Ostor A, Wassenberg S, Chen N, Wang C, Garg V, et al.
Rheumatol Ther
. 2017 May;
4(1):97.
PMID: 28474206
No abstract available.